Key statistics
As of last trade Medigene AG (MDG2:VIE) traded at 1.75, 2.40% above its 52-week low of 1.71, set on Sep 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.71 |
---|---|
High | 1.75 |
Low | 1.71 |
Bid | 1.70 |
Offer | 1.79 |
Previous close | 1.71 |
Average volume | 420.00 |
---|---|
Shares outstanding | 14.74m |
Free float | 14.30m |
P/E (TTM) | -- |
Market cap | 25.82m EUR |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Sep 05 2024.
More ▼
Announcements
- Medigene Announces U.S. FDA Clearance of IND Application for MDG1015, a First-in-Class, Third Generation T Cell Receptor Engineered T Cell (TCR-T) Therapy for Multiple Solid Tumor Indications
- Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform
- Medigene to Present at Upcoming Investor Conferences
- Medigene AG implements announced 2:1 share capital reduction and consolidation of the shares effective August 29, 2024
- Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update
- Medigene AG to Report Half-Year 2024 Financial Results on August 14, 2024
- Medigene and WuXi Biologics Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
- Medigene to Present at ESMO Congress 2024
- Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China
- Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness
More ▼